Fortis Healthcare said the Tokyo District Court has dismissed all claims filed by promoter shareholder Northern TK Venture against Daiichi Sankyo and ordered NTK to bear litigation costs. NTK disagrees with the September 10, 2026 judgment and is evaluating available legal remedies. The ruling is a setback for the promoter’s litigation strategy but does not directly affect Fortis Healthcare’s operating results.
Fortis Promoter NTK Loses Daiichi Sankyo Case in Tokyo Court
Tokyo District Court dismissed all claims filed by Northern TK Venture on September 10, 2026.
NTK was also ordered to bear the costs of the litigation.
Reader Takeaway: Fortis operations are unaffected, but its promoter has suffered a material legal setback.
What just happened
Fortis Healthcare Limited disclosed that the Tokyo District Court has dismissed all claims brought by Northern TK Venture Pte Ltd, a promoter shareholder of Fortis, against Daiichi Sankyo Company Limited.
The judgment was delivered on September 10, 2026. The court also directed NTK to bear the litigation costs.
NTK has said it disagrees with the judgment and continues to believe in the merits of its position. It is reviewing the ruling with legal advisers and evaluating available remedies.
Why this matters
The case is linked to the long-running dispute surrounding NTK’s investment in Fortis and proposed open offers.
NTK had filed its claim in the Tokyo District Court in October 2023. Earlier disclosures said it sought damages exceeding ¥20 billion from Daiichi Sankyo, alleging that Daiichi Sankyo had caused losses by preventing NTK from proceeding with open offers involving Fortis Healthcare and Fortis Malar Hospitals.
The September 2026 ruling rejects those claims at the Tokyo District Court level.
For Fortis shareholders, however, the distinction is important: the litigation was brought by NTK against Daiichi Sankyo. Fortis Healthcare itself was not the claimant seeking the damages described in the dispute.
What changes now
There is no direct operating or earnings impact on Fortis Healthcare disclosed from this judgment.
The immediate consequence falls on NTK, whose claims have been dismissed and which must bear litigation costs. Whether the dispute continues will depend on the legal remedies NTK chooses after reviewing the judgment.
The filing does not state that an appeal has already been filed.
Risks to watch
The principal uncertainty is whether NTK challenges the Tokyo District Court judgment and, if so, how long further proceedings could continue.
Investors should avoid treating the judgment as a direct liability for Fortis unless subsequent filings establish a financial consequence for the listed company itself.
What to track next
The next material disclosure would be NTK’s decision on further legal action. Investors should also watch for any clarification on whether the judgment affects promoter-level plans connected with the earlier Fortis open-offer dispute.
